Simultaneous determination of a novel anticancer drug, TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction.
A simple and rapid method for the analysis of a novel anticancer drug, TAS-103, and its metabolite demethyl-TAS-103 in monkey plasma has been developed. This method is based on high-performance liquid chromatography with visible detection at 460 nm after solid-phase extraction with a Sep-Pak Vac PS-2 cartridge. The extraction recoveries of each compound, including the internal standard TAS-1-1018, were from 88 to 102%. The quantitation limit of each compound was 5.0 ng/ml in 0.5 ml of plasma. The coefficients of variation for each compound ranged from 0.9 to 4.9%, and relative errors for each compound ranged from -3.8 to 4.6%. Both compounds in monkey plasma were stable at -80 degrees C for 39 days and the extracts were stable at ambient temperature for 24 h. This method has been demonstrated to be useful for the pharmacokinetic study of TAS-103 in monkey plasma after intravenous administration.
Azuma
R
R
Pharmacokinetics Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Urakawa
A
A
D000634:Aminoquinolines / Q000097:blood* / Q000493:pharmacokinetics; D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D007192:Indenes / Q000097:blood* / Q000493:pharmacokinetics; D008252:Macaca fascicularis; D008297:Male; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007192:Indenes; C106647:6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one